Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CTX.WA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-1.16
vs -2.64
Q1.23
N/A
-3.09
vs -2.69
Q2.23
N/A
-6.91
vs -2.36
Q3.23
N/A
-3.72
vs -1.85
Q4.23
N/A
-2.47
vs -1.16
Q1.24
N/A
-2.04
vs -3.09
Q2.24
N/A
-2.14
vs -6.91
Q3.24
N/A
-2.20
vs -3.72
Q4.24
N/A
-1.59
vs -2.47
Q1.25
N/A
NA
vs -2.04
Sales Growth
YoY
Current
Estimates
Q4.22
+355%
5.8M vs 1.3M
Q1.23
+49%
1.5M vs 1M
Q2.23
+98%
2.4M vs 1.2M
Q3.23
+154%
2.8M vs 1.1M
Q4.23
+11%
6.5M vs 5.8M
Q1.24
+192%
4.5M vs 1.5M
Q2.24
+105%
4.8M vs 2.4M
Q3.24
+25%
3.5M vs 2.8M
Q4.24
-54%
3M vs 6.5M
Q1.25
-42%
2.6M vs 4.5M
Return on Equity
QoQ
Q2.23
-52%
-0.52
vs -0.16
Q3.23
-39%
-0.39
vs -0.52
Q4.23
-17%
-0.17
vs -0.39
Q1.24
-16%
-0.16
vs -0.17
Q2.24
-20%
-0.20
vs -0.16
Q3.24
-25%
-0.25
vs -0.20
Q4.24
-14%
-0.14
vs -0.25
Q1.25
-20%
-0.20
vs -0.14
Institutionnal Ownership
Forecast
2855%2026-Revenue
248%2026-EPS
-392%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
WSE
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
Volume Buzz
-67%
Earning Acce
No
Dist 52w H.
55%Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CTX.WA compares to sector?